UY30302A1 - Formulaciones de pepticuerpos terapeuticos liofilizados - Google Patents
Formulaciones de pepticuerpos terapeuticos liofilizadosInfo
- Publication number
- UY30302A1 UY30302A1 UY30302A UY30302A UY30302A1 UY 30302 A1 UY30302 A1 UY 30302A1 UY 30302 A UY30302 A UY 30302A UY 30302 A UY30302 A UY 30302A UY 30302 A1 UY30302 A1 UY 30302A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formulations
- liofilized
- therapeutic
- therapeutic peptibodies
- peptibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
Abstract
La presente invencion proporciona formulaciones estables a largo plazo de un pepticuerpo terapéutico liofilizado y métodos para hacer una composicion liofilizada que comprende un pepticuerpo terapéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79399706P | 2006-04-21 | 2006-04-21 | |
US11/788,697 US9283260B2 (en) | 2006-04-21 | 2007-04-19 | Lyophilized therapeutic peptibody formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30302A1 true UY30302A1 (es) | 2007-10-31 |
Family
ID=38625630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30302A UY30302A1 (es) | 2006-04-21 | 2007-04-20 | Formulaciones de pepticuerpos terapeuticos liofilizados |
Country Status (38)
Country | Link |
---|---|
US (2) | US9283260B2 (es) |
EP (6) | EP2018183B1 (es) |
JP (6) | JP5432705B2 (es) |
KR (2) | KR101227278B1 (es) |
CN (2) | CN107789325A (es) |
AR (1) | AR060617A1 (es) |
AU (1) | AU2007240656A1 (es) |
BR (1) | BRPI0710508B8 (es) |
CA (1) | CA2649292C (es) |
CR (3) | CR20170130A (es) |
CY (1) | CY1118038T1 (es) |
DK (1) | DK2018183T3 (es) |
EA (2) | EA022424B1 (es) |
ES (1) | ES2599318T3 (es) |
GE (1) | GEP20156253B (es) |
HR (1) | HRP20161653T1 (es) |
HU (1) | HUE032144T2 (es) |
IL (3) | IL194653A (es) |
JO (1) | JO3324B1 (es) |
LT (1) | LT2018183T (es) |
MA (1) | MA30474B1 (es) |
MX (1) | MX2008013393A (es) |
MY (1) | MY162816A (es) |
NO (1) | NO344947B1 (es) |
NZ (1) | NZ596367A (es) |
PE (1) | PE20081196A1 (es) |
PH (1) | PH12014502880A1 (es) |
PL (1) | PL2018183T3 (es) |
PT (1) | PT2018183T (es) |
RS (1) | RS55428B1 (es) |
SG (2) | SG182887A1 (es) |
SI (1) | SI2018183T1 (es) |
TN (1) | TNSN08391A1 (es) |
TW (1) | TWI352598B (es) |
UA (2) | UA116080C2 (es) |
UY (1) | UY30302A1 (es) |
WO (1) | WO2007124090A2 (es) |
ZA (1) | ZA200808485B (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2279649T3 (es) * | 1998-10-23 | 2007-08-16 | Amgen Inc. | Compuestos trombopoyeticos. |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
CN100553678C (zh) | 1999-02-22 | 2009-10-28 | 巴克斯特国际有限公司 | 新的无白蛋白的因子ⅷ制剂 |
CA2375827C (en) | 1999-06-01 | 2017-01-10 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
IL158376A0 (en) | 2001-04-13 | 2004-05-12 | Biogen Inc | Antibodies to vla-1 |
ES2397441T5 (es) | 2006-02-13 | 2022-09-14 | Daiichi Sankyo Co Ltd | Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
AU2011265555B2 (en) * | 2006-04-21 | 2016-03-10 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
CN101494978A (zh) | 2006-05-25 | 2009-07-29 | 比奥根艾迪克Ma公司 | 治疗中风的方法 |
US8999383B2 (en) * | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
ES2706296T3 (es) | 2008-11-07 | 2019-03-28 | Univ Connecticut | Formulaciones de Factor VIII |
WO2011038139A1 (en) | 2009-09-23 | 2011-03-31 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
BR112012017982A2 (pt) * | 2010-01-19 | 2016-05-03 | Hanmi Science Co Ltd | formulações líquidas para conjugado de eritropoietina de longa ação |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
EA201390810A1 (ru) | 2010-12-02 | 2013-09-30 | Онколитикс Байотек Инк. | Жидкие вирусные составы |
CN103269716B (zh) | 2010-12-02 | 2015-05-27 | 昂科利蒂克斯生物科技公司 | 冻干病毒制剂 |
JP5759211B2 (ja) * | 2011-03-11 | 2015-08-05 | 三洋化成工業株式会社 | 凍結乾燥方法 |
AU2012275346B2 (en) | 2011-06-29 | 2016-03-17 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
DE102011055889B4 (de) * | 2011-11-30 | 2013-08-01 | Otc Gmbh | Verfahren zur Herstellung eines Protein-Hydrolysates |
CN102586217A (zh) * | 2011-12-16 | 2012-07-18 | 深圳市海普瑞药业股份有限公司 | 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法 |
RU2482128C1 (ru) * | 2011-12-28 | 2013-05-20 | Замертон Холдингс Лимитед | Пептиды, обладающие цитопротекторной активностью |
WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
EP2644186A1 (en) | 2012-03-26 | 2013-10-02 | OTC GmbH | Hair conditioning composition for permanent and semi-permanent hair coloration applications |
US20150335752A1 (en) * | 2012-06-25 | 2015-11-26 | Emergent Product Development Gaithersburg Inc. | Temperature Stable Vaccine Formulations |
EA201590247A1 (ru) | 2012-07-19 | 2015-10-30 | Алетиа Байотерапьютикс Инк. | Антитела к siglec-15 |
EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
KR20150140294A (ko) * | 2013-03-15 | 2015-12-15 | 암젠 인코퍼레이티드 | 사람 대상에서 미오스타틴 길항작용 |
CN104274827B (zh) * | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
WO2015035405A1 (en) * | 2013-09-09 | 2015-03-12 | Pinta Biotherapeutics, Inc. | Myostatin antagonist for treatment of pew in esrd patients |
US10383911B2 (en) * | 2013-11-07 | 2019-08-20 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Storage stable lyophilized tripeptide formulations |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015085233A1 (en) * | 2013-12-06 | 2015-06-11 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
WO2015100344A1 (en) | 2013-12-27 | 2015-07-02 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
US10918698B2 (en) * | 2014-03-29 | 2021-02-16 | Intas Pharmaceuticals Ltd. | Lyophilized pharmaceutical composition of Fc-peptide fusion protein |
CN114057895A (zh) | 2014-05-28 | 2022-02-18 | 诺诺公司 | TAT-NR2B9c的氯盐 |
EA201692568A1 (ru) * | 2014-06-13 | 2017-05-31 | Санта Мария Биотерапевтикс, Инк. | Составы с полипептидами-рецепторами и связанные с ними способы |
CN107073082B (zh) * | 2014-08-20 | 2021-04-30 | 博尔托拉制药公司 | Xa因子解毒剂的冻干制剂 |
JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
US10857229B2 (en) | 2015-04-30 | 2020-12-08 | Amgen Inc. | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane |
EP3297660A2 (en) | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
EP3389696A4 (en) | 2015-12-17 | 2019-08-14 | The Johns Hopkins University | TREATING SYSTEMIC SCLEROSIS WITH DEATH RECEPTOR AGONISTS |
JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
EP3454903A4 (en) * | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
JP2017155046A (ja) * | 2017-04-05 | 2017-09-07 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
CA3072600A1 (en) | 2017-09-15 | 2019-03-21 | Amgen Inc. | Process for lyophilized pharmaceutical formulation of a therapeutic protein |
MA50174A (fr) * | 2017-09-18 | 2020-07-29 | Amgen Inc | Formules de protéines de fusion vegfr-fc |
CN108159413B (zh) * | 2018-01-10 | 2021-07-06 | 杭州洪桥中科基因技术有限公司 | 一种动物用冻干活疫苗及其制备方法 |
GB201804835D0 (en) * | 2018-03-26 | 2018-05-09 | Ge Healthcare As | Formulation and method of preparation |
SG11202013248YA (en) * | 2018-07-31 | 2021-02-25 | Amgen Inc | Pharmaceutical formulations of masked antibodies |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
EP3744319B1 (en) | 2019-05-28 | 2022-10-19 | Ilkogen Ilac Sanayi Ve Ticaret A.S. | A stable lyophilized formulation for hybrid fc fused g-csf |
JP2019178154A (ja) * | 2019-06-18 | 2019-10-17 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
JP7471688B2 (ja) * | 2019-12-03 | 2024-04-22 | 中國醫藥大學 | オリゴペプチド、検出キット及び医薬組成物 |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CA3211476A1 (en) * | 2021-03-31 | 2022-10-06 | Hangzhou Exegenesis Bio Ltd. | Fusion molecules targeting vegf and angiopoietin and uses thereof |
AR127813A1 (es) | 2021-12-01 | 2024-02-28 | UCB Biopharma SRL | FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG |
US20240076597A1 (en) * | 2022-09-02 | 2024-03-07 | Terumo Bct, Inc. | Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes |
CN118126120A (zh) * | 2023-09-14 | 2024-06-04 | 海南大学 | 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
DE3244265A1 (de) | 1982-11-30 | 1984-05-30 | Cassella Ag, 6000 Frankfurt | Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung |
US4503235A (en) | 1983-03-11 | 1985-03-05 | Warner-Lambert Company | Process for producing 4-carbamoyl-1H-imidazolium-5-olate |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
DE69332485T2 (de) | 1992-08-11 | 2003-11-13 | Harvard College | Immunmodulierende peptide |
GB9225448D0 (en) | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5786331A (en) | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5880096A (en) | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5844929A (en) * | 1994-02-24 | 1998-12-01 | British Telecommunications Public Limited Company | Optical device with composite passive and tapered active waveguide regions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
AU693478B2 (en) | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
IL116026A (en) | 1994-11-22 | 2005-08-31 | Rhone Poulenc Rorer Sa | Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses |
US5888763A (en) | 1994-12-30 | 1999-03-30 | The Rockefeller University | Peptides specific for the first Crk-SH3 domain |
JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Il−12用処方 |
IL113159A0 (en) | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
EP1516628B1 (en) * | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US5746516A (en) | 1995-08-11 | 1998-05-05 | Hitachi Powdered Metals Co., Ltd. | Porous bearing system having internal grooves and electric motor provided with the same |
US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
JPH09151200A (ja) | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US5714577A (en) | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
IL117223A0 (en) | 1996-02-22 | 1996-06-18 | Yeda Res & Dev | Antipathogenic polypeptides and compositions comprising them |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU2597897A (en) | 1996-03-28 | 1997-10-17 | Brigham And Women's Hospital | Peptide ligands of the urokinase receptor |
IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
FR2748028B1 (fr) | 1996-04-30 | 1998-08-14 | Lab Francais Du Fractionnement | Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant |
CA2257108A1 (en) | 1996-06-07 | 1997-12-11 | Takeda Chemical Industries, Ltd. | Novel peptides and production and use thereof |
US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
CA2265484C (en) | 1996-09-10 | 2008-12-02 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
JP2001501619A (ja) * | 1996-10-04 | 2001-02-06 | アムジェン インコーポレーテッド | mplリガンドを含有する医薬組成物 |
JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
US5955431A (en) | 1997-02-05 | 1999-09-21 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
CZ302262B6 (cs) | 1997-04-16 | 2011-01-19 | Amgen Inc. | Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající |
US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP1028971A2 (en) | 1997-11-07 | 2000-08-23 | ConjuChem, Inc. | Novel conjugates of rgd-containing peptides and endogenous carriers |
AU2481399A (en) | 1998-01-29 | 1999-08-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Variant peptide ligands that selectively induce apoptosis |
US6423685B1 (en) | 1998-03-05 | 2002-07-23 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
US6235872B1 (en) | 1998-03-12 | 2001-05-22 | The Burnham Institute | Proapoptotic peptides dependence polypeptides and methods of use |
AU3189299A (en) | 1998-03-20 | 1999-10-11 | Chugai Pharmaceutical Co., Ltd. | Peptide ligands for the erythropoietin receptor |
EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
EP1075270B1 (en) | 1998-04-06 | 2005-06-15 | Advanced Immunit, Inc. | Short peptide for treatment of neurological degenerative diseases |
JP2002512982A (ja) | 1998-04-28 | 2002-05-08 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | Peg−lhrhアナログ複合体 |
EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
PT1078002E (pt) | 1998-05-22 | 2008-09-02 | Abbott Lab | Fármacos de péptidos antiangiogénicos |
US5932548A (en) | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
WO2000001402A1 (en) | 1998-07-02 | 2000-01-13 | Envision Biomedical Consulting | Antiproliferative and antiviral proteins and peptides |
US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
WO2000011028A2 (en) | 1998-08-21 | 2000-03-02 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from il-2 and analogues thereof |
BR9915548A (pt) | 1998-10-16 | 2001-08-14 | Biogen Inc | Proteìnas de fusão de interferon-beta e usos |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2279649T3 (es) | 1998-10-23 | 2007-08-16 | Amgen Inc. | Compuestos trombopoyeticos. |
WO2000047740A2 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
US6853809B2 (en) | 2001-01-30 | 2005-02-08 | Koninklijke Philips Electronics N.V. | Camera system for providing instant switching between wide angle and full resolution views of a subject |
CN1970077A (zh) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
RU2180233C1 (ru) | 2001-06-26 | 2002-03-10 | Общество с ограниченной ответственностью "Протеиновый контур" | Способ получения жидких лекарственных форм рекомбинантных белков |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US20040247588A1 (en) | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
ES2359562T3 (es) | 2002-12-20 | 2011-05-24 | Amgen, Inc. | Agentes de unión que inhiben miostatina. |
MX2007000216A (es) | 2004-07-08 | 2007-03-15 | Amgen Inc | Peptidos terapeuticos. |
CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP3035305B1 (en) | 2014-12-18 | 2016-11-16 | Axis AB | Enclosure and arrangement for recess mounting of a camera or camera head |
-
2007
- 2007-04-19 US US11/788,697 patent/US9283260B2/en active Active
- 2007-04-19 JO JOP/2007/0154A patent/JO3324B1/ar active
- 2007-04-20 EA EA201270625A patent/EA022424B1/ru not_active IP Right Cessation
- 2007-04-20 RS RS20161076A patent/RS55428B1/sr unknown
- 2007-04-20 UA UAA201209639A patent/UA116080C2/uk unknown
- 2007-04-20 LT LTEP07775901.7T patent/LT2018183T/lt unknown
- 2007-04-20 EP EP07775901.7A patent/EP2018183B1/en active Active
- 2007-04-20 SG SG2011029154A patent/SG182887A1/en unknown
- 2007-04-20 CN CN201711043851.4A patent/CN107789325A/zh active Pending
- 2007-04-20 KR KR1020087028391A patent/KR101227278B1/ko active IP Right Grant
- 2007-04-20 HU HUE07775901A patent/HUE032144T2/en unknown
- 2007-04-20 AU AU2007240656A patent/AU2007240656A1/en not_active Abandoned
- 2007-04-20 EP EP12187301.2A patent/EP2594286A1/en not_active Withdrawn
- 2007-04-20 CN CNA200780022610XA patent/CN101484185A/zh active Pending
- 2007-04-20 TW TW096114064A patent/TWI352598B/zh active
- 2007-04-20 GE GEAP200710981A patent/GEP20156253B/en unknown
- 2007-04-20 EP EP12187304.6A patent/EP2594288A1/en not_active Withdrawn
- 2007-04-20 BR BRPI0710508A patent/BRPI0710508B8/pt active IP Right Grant
- 2007-04-20 PE PE2007000494A patent/PE20081196A1/es active IP Right Grant
- 2007-04-20 KR KR1020127022549A patent/KR101236042B1/ko active IP Right Grant
- 2007-04-20 UY UY30302A patent/UY30302A1/es active IP Right Grant
- 2007-04-20 CR CR20170130A patent/CR20170130A/es unknown
- 2007-04-20 EP EP12187298.0A patent/EP2594285B1/en active Active
- 2007-04-20 SI SI200731856A patent/SI2018183T1/sl unknown
- 2007-04-20 EP EP12187302.0A patent/EP2594287A1/en not_active Withdrawn
- 2007-04-20 EP EP12187297.2A patent/EP2594284A1/en not_active Withdrawn
- 2007-04-20 MY MYPI20084070A patent/MY162816A/en unknown
- 2007-04-20 AR ARP070101709A patent/AR060617A1/es not_active Application Discontinuation
- 2007-04-20 ES ES07775901.7T patent/ES2599318T3/es active Active
- 2007-04-20 DK DK07775901.7T patent/DK2018183T3/en active
- 2007-04-20 WO PCT/US2007/009712 patent/WO2007124090A2/en active Application Filing
- 2007-04-20 PL PL07775901T patent/PL2018183T3/pl unknown
- 2007-04-20 NZ NZ596367A patent/NZ596367A/xx unknown
- 2007-04-20 SG SG10201501296SA patent/SG10201501296SA/en unknown
- 2007-04-20 JP JP2009506615A patent/JP5432705B2/ja active Active
- 2007-04-20 CA CA2649292A patent/CA2649292C/en active Active
- 2007-04-20 PT PT77759017T patent/PT2018183T/pt unknown
- 2007-04-20 UA UAA200813378A patent/UA99815C2/ru unknown
- 2007-04-20 MX MX2008013393A patent/MX2008013393A/es active IP Right Grant
- 2007-04-20 EA EA200802170A patent/EA017085B1/ru not_active IP Right Cessation
-
2008
- 2008-10-06 ZA ZA200808485A patent/ZA200808485B/xx unknown
- 2008-10-07 IL IL194653A patent/IL194653A/en active IP Right Grant
- 2008-10-07 TN TNP2008000391A patent/TNSN08391A1/en unknown
- 2008-11-14 CR CR10442A patent/CR10442A/es unknown
- 2008-11-20 NO NO20084893A patent/NO344947B1/no unknown
- 2008-11-20 MA MA31391A patent/MA30474B1/fr unknown
-
2013
- 2013-02-27 IL IL224966A patent/IL224966A/en active IP Right Grant
- 2013-09-27 JP JP2013201931A patent/JP5873854B2/ja active Active
-
2014
- 2014-06-12 CR CR20140274A patent/CR20140274A/es unknown
- 2014-12-23 PH PH12014502880A patent/PH12014502880A1/en unknown
-
2015
- 2015-10-22 JP JP2015208065A patent/JP6356106B2/ja active Active
-
2016
- 2016-01-29 US US15/011,229 patent/US10166189B2/en active Active
- 2016-09-20 CY CY20161100932T patent/CY1118038T1/el unknown
- 2016-09-29 IL IL248156A patent/IL248156B/en active IP Right Grant
- 2016-12-06 HR HRP20161653TT patent/HRP20161653T1/hr unknown
-
2018
- 2018-06-12 JP JP2018111720A patent/JP6787953B2/ja active Active
-
2020
- 2020-07-30 JP JP2020128961A patent/JP2021006525A/ja active Pending
-
2022
- 2022-08-18 JP JP2022130437A patent/JP2022166219A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30302A1 (es) | Formulaciones de pepticuerpos terapeuticos liofilizados | |
CR10528A (es) | Proceso para producir poxvirus y composiciones de poxvirus | |
CL2017001847A1 (es) | Una formulación sólida de dosificación farmacéutica | |
CR11106A (es) | Inhibidores de cinasa p710 s6 | |
CR20110110A (es) | Composicion farmaceutica | |
UY30495A1 (es) | Formulaciones de modificador de respuesta inmune | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
AR058691A1 (es) | Sonda microquirurgica | |
GT200800276A (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
HN2007000437A (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
CO6210786A2 (es) | Implemento de cuidado oral que alberga un agente de cuidado oral | |
BRPI0815170A2 (pt) | Composição farmacêutica que compreende um inibidor de sglt 2 | |
CR9246A (es) | Formulaciones terapeuticas del factor de crecimiento de queratinocitos | |
HN2008000278A (es) | Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
ECSP12012208A (es) | Formulaciones orales y sales lipofílicas de metilnaltrexona | |
PA8624601A1 (es) | Macrolidos y metodos para producir los mismos | |
CR10505A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden | |
BRPI0716765A2 (pt) | mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço | |
CR10280A (es) | Anticuerpos de la efgl7 y metodos de uso | |
UY31273A1 (es) | Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 | |
CR11406A (es) | Conjugados de neurturina novedosos para uso farmaceutico | |
SV2009003287A (es) | Agentes para combatir parasitos en animales | |
GT200500031A (es) | Procesos para la preparacion de haluros de arilalquilsulfonilo y haluros de heteroarilalquilsulfonilo | |
PA8846401A1 (es) | Sinergismo antibiótico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20190423 |